Cantor: Relypsa Sale Makes Sense

Analysts at Cantor said the potential sale of Relypsa Inc

makes sense. Earlier, Reuters reported the biopharma company is exploring a sale following a number of overtures from potential buyers. http://finance.yahoo.com/news/biotechnology-company-relypsa-explores-potential-165301759.html Relypsa is working with investment bank Centerview Partners Holdings LLC to review offers, the report said citing people familiar with the matter. Shares of Relypsa, which makes Veltassa for the treatment of hyperkalemia ( a blood disorder), jumped as much as 67 percent on the news. "This is consistent with our view that the shares have strategic value given the larger opportunity in the hyperkalemia and limited competition. Our PT is $42 which is based on the average of two valuation methodologies: discounted revenue and DCF," Cantor said in an email note. Based on AstraZeneca plc (ADR)

's takeout of ZS Pharma, Cantor sees value of about $3 billion, or $75 per share. The brokerage has a Buy rating on Relypsa shares, which were currently up 63.47 percent to $23.72.